Search - tctmd.com

Displaying 581 - 600 of 2250

Sort: Relevancy | Date

News Industry News

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

September 21, 2015

Presentation Aortovascular 2015

Novel Anticoagulants for Venous Thromboembolism: Will this change your practice?

Presenter: Michael R. Jaff

September 18, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Industry News

Ventrix Initiates Clinical Trial of VentriGel™

September 17, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Industry News

MedLumics Technology Validated for Real-time Assessment of Catheter Ablation Treatment of Atrial Fibrillation in Pre-clinical Feasibility Study

September 16, 2015

News Daily News

Registry Charts Trends in Mechanical Circulatory Support During PCI

L.A. McKeown

September 14, 2015

News Daily News

OPTIMAX: Prometedores Primeros Resultados en Humanos de un Stent Biocompatible de Cobalto-Cromo

Yael L. Maxwell

September 14, 2015

News Daily News

OPTIMAX: First-in-Human Results Promising for Biocompatible Cobalt-Chromium Stent

Yael L. Maxwell

September 14, 2015

News Daily News

OPTIMAX：生物相容性钴铬支架的首例人类结果前景看好

Yael L. Maxwell

September 14, 2015

News Industry News

First Patient Enrolled in CeloNova’s e-COBRA Clinical Registry

September 14, 2015

News Daily News

Short-term Readmission Rates Similar After TAVR vs SAVR

Todd Neale

September 10, 2015

News Daily News

Los Índices de Rehospitalizaciones a Corto Plazo son Similares Post TAVR vs SAVR

Todd Neale

September 10, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

PRESERVATION I: Bioabsorbable Cardiac Matrix Does Not Benefit STEMI Patients

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

PLATFORM: More Than 60% of Planned Catheterizations Cancelled When CT-Derived FFR Guides Care

L.A. McKeown

September 02, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

ABSORB Trials Pit BRS Against Second-Generation DES

Caitlin E. Cox

September 02, 2015

Presentation ESC 2015

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Presenter: Takeshi Kimura

September 01, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

Advertisement

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

Novel Anticoagulants for Venous Thromboembolism: Will this change your practice?

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Ventrix Initiates Clinical Trial of VentriGel™

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

MedLumics Technology Validated for Real-time Assessment of Catheter Ablation Treatment of Atrial Fibrillation in Pre-clinical Feasibility Study

Registry Charts Trends in Mechanical Circulatory Support During PCI

OPTIMAX: Prometedores Primeros Resultados en Humanos de un Stent Biocompatible de Cobalto-Cromo

OPTIMAX: First-in-Human Results Promising for Biocompatible Cobalt-Chromium Stent

OPTIMAX：生物相容性钴铬支架的首例人类结果前景看好

First Patient Enrolled in CeloNova’s e-COBRA Clinical Registry

Short-term Readmission Rates Similar After TAVR vs SAVR

Los Índices de Rehospitalizaciones a Corto Plazo son Similares Post TAVR vs SAVR

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

PRESERVATION I: Bioabsorbable Cardiac Matrix Does Not Benefit STEMI Patients

PLATFORM: More Than 60% of Planned Catheterizations Cancelled When CT-Derived FFR Guides Care

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

ABSORB Trials Pit BRS Against Second-Generation DES

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content